GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (NAS:AVXL) » Definitions » Net Cash per Share

Anavex Life Sciences (Anavex Life Sciences) Net Cash per Share : $1.60 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Anavex Life Sciences Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Anavex Life Sciences's Net Cash per Share for the quarter that ended in Dec. 2023 was $1.60.

The historical rank and industry rank for Anavex Life Sciences's Net Cash per Share or its related term are showing as below:

AVXL' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.11   Med: 8.72   Max: 74
Current: 2.18

During the past 13 years, the highest Price-to-Net-Cash Ratio of Anavex Life Sciences was 74.00. The lowest was 2.11. And the median was 8.72.

AVXL's Price-to-Net-Cash is ranked better than
69.43% of 867 companies
in the Biotechnology industry
Industry Median: 3.87 vs AVXL: 2.18

Anavex Life Sciences Net Cash per Share Historical Data

The historical data trend for Anavex Life Sciences's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences Net Cash per Share Chart

Anavex Life Sciences Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.33 0.35 1.86 1.78 1.69

Anavex Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.67 1.74 1.77 1.69 1.60

Competitive Comparison of Anavex Life Sciences's Net Cash per Share

For the Biotechnology subindustry, Anavex Life Sciences's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anavex Life Sciences's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Anavex Life Sciences's Price-to-Net-Cash falls into.



Anavex Life Sciences Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Anavex Life Sciences's Net Cash per Share for the fiscal year that ended in Sep. 2023 is calculated as

Net Cash per Share (A: Sep. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(151.024-12.534-0)/82.0665
=1.69

Anavex Life Sciences's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(143.765-12.495-0)/82.0865
=1.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anavex Life Sciences  (NAS:AVXL) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Anavex Life Sciences Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Anavex Life Sciences (Anavex Life Sciences) Business Description

Traded in Other Exchanges
Address
630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
Executives
Christopher U Missling director, officer: President, CEO, CFO, Treasurer, other: Secretary 61 MOULTON ST, CAMBRIDGE MA 02138
Athanasios Skarpelos 10 percent owner 14,RUE KLEBERG, GENEVA V8 CH-1201
Jiong Ma director 445 PARK AVENUE, 9TH FLOOR, NEW YORK NY 10022
Elliot Favus director 51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10091
Donhauser Peter D.o. director REGINA-KIRCHMAIER STRASSE 4, KAUFBEUREN 2M 87600
Sandra Boenisch officer: PFO & Treasurer 51 WEST 52ND STREET, 7TH FLOOR, NEW YORK NY 10019
Claus Vander Velden director PO BOX MUENSTEREIFELER ST., COLOGNE 2M 50937
Steffen Thomas director FALLMERAYER STR. 19, MUNICH 2M 80796
Bernd Metzner director 51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10019
George F Tidmarsh director, officer: Executive Director
John Robert Chisholm director 16308 36A AVENUE, SURREY A1 V3S 0X5
William Sean Lowry director 1172 BAY STREET, SUITE 300, ONTARIO Z4 M5S1L9
David L. Tousley director 14610 PAWNEE LANE, LEAWOOD KS 66224
Harvey Lalach director, officer: President CEO CFO 4837 CANYON RIDGE CRESENT, KELOWNA A1 V1W 4A1
Alison E. Ayers director 27 O'CONNOR CIRCLE, WEST ORANGE NJ 07052

Anavex Life Sciences (Anavex Life Sciences) Headlines

From GuruFocus